
    the trial ended early due to gi intolerability and treatment-emergent resistance.
  
['infection, human immunodeficiency virus']
['bms-955176', 'efv', 'tdf/ftc']

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Men and non-pregnant women, at least 18 years of age

          -  Antiretroviral treatment-naïve; defined as no current or previous exposure to > 1 week
             of an antiretroviral drug

          -  Plasma HIV-1 RNA ≥ 1000 copies/mL

          -  CD4 T-cell count > 200 cells/mm3

        Exclusion Criteria:

          -  Resistance or partial resistance to any study drug determined by tests at Screening

          -  Current or historical genotypic and/or phenotypic drug resistance testing showing
             certain resistance mutations to EFV, TDF, FTC, Protease Inhibitors

          -  Chronic hepatitis B virus (HBV)/ hepatitis C virus (HCV)

          -  Blood tests that indicate normal liver function

          -  Hemoglobin < 8.0 g/dL, platelets < 50,000 cells/mm3
      